Ultragenyx Pharmaceutical Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 9.0% of BeiGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and BeiGene's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and BeiGene's revenue, earnings per share and valuation.

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and BeiGene, as provided by MarketBeat.com.

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 20.68%. BeiGene has a consensus price target of $319.3750, indicating a potential upside of 4.53%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than BeiGene.

Summary

Ultragenyx Pharmaceutical beats BeiGene on 10 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 2.5% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Ultragenyx Pharmaceutical and Royalty Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Royalty Pharma's revenue, earnings per share and valuation.

Royalty Pharma has lower revenue, but higher earnings than Ultragenyx Pharmaceutical.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and Royalty Pharma, as provided by MarketBeat.com.

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 20.68%. Royalty Pharma has a consensus price target of $51.8750, indicating a potential upside of 23.90%. Given Royalty Pharma's higher probable upside, analysts clearly believe Royalty Pharma is more favorable than Ultragenyx Pharmaceutical.

Summary

Royalty Pharma beats Ultragenyx Pharmaceutical on 5 of the 9 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and Genmab A/S, as provided by MarketBeat.com.

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 20.68%. Genmab A/S has a consensus price target of $42.1429, indicating a potential upside of 19.62%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Insider and Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Genmab A/S's revenue, earnings per share and valuation.

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Genmab A/S's net margins, return on equity and return on assets.

Summary

Genmab A/S beats Ultragenyx Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Horizon Therapeutics Public and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Risk and Volatility

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Horizon Therapeutics Public and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Horizon Therapeutics Public presently has a consensus target price of $111.3636, indicating a potential upside of 19.40%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.68%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Horizon Therapeutics Public.

Insider and Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Horizon Therapeutics Public and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Insider & Institutional Ownership

4.3% of CureVac shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares CureVac and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for CureVac and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

CureVac currently has a consensus target price of $58.3333, indicating a potential downside of 46.63%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.68%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than CureVac.

Valuation & Earnings

This table compares CureVac and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

CureVac has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Summary

Ultragenyx Pharmaceutical beats CureVac on 5 of the 9 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Catalent and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Volatility and Risk

Catalent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Insider and Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Catalent and Ultragenyx Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Catalent has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Catalent and Ultragenyx Pharmaceutical, as reported by MarketBeat.

Catalent currently has a consensus target price of $125.1250, indicating a potential upside of 13.13%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.68%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Catalent.

Summary

Catalent beats Ultragenyx Pharmaceutical on 9 of the 14 factors compared between the two stocks.